{"id":"mirogabalin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent calcium channel subunit alpha-2/delta-1","category":"target"},{"label":"CACNA2D1","category":"gene"},{"label":"CACNA2D2","category":"gene"},{"label":"N02BF03","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetic peripheral neuropathy","category":"indication"},{"label":"Peripheral neuropathic pain","category":"indication"},{"label":"Postherpetic neuralgia","category":"indication"},{"label":"Daiichi Sankyo Company, Limited","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Daiichi Sankyo","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MIROGABALIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:33:13.847014+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:33:18.836238+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIROGABALIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:33:19.133517+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545125/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:33:19.833506+00:00"}},"allNames":"tarlige","offLabel":[],"synonyms":["mirogabalin","mirogabalin besilate","tarlige","DS 5565"],"timeline":[{"date":"2019-08-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Daiichi Sankyo Company, Limited)"}],"aiSummary":"Mirogabalin, also known as Tarlige, is a small molecule modality developed by Daiichi Sankyo Company, Limited. It targets the voltage-dependent calcium channel subunit alpha-2/delta-1, which plays a crucial role in pain transmission. Mirogabalin is approved for the treatment of diabetic peripheral neuropathy, peripheral neuropathic pain, and postherpetic neuralgia. The commercial status of Mirogabalin is not explicitly stated, but it is still owned by Daiichi Sankyo Company, Limited. Key safety considerations include its mechanism of action, which may have implications for patients with certain medical conditions.","approvals":[{"date":"2019-08-01","orphan":false,"company":"DAIICHI SANKYO COMPANY, LIMITED","regulator":"PMDA"}],"brandName":"Tarlige","ecosystem":[{"indication":"Diabetic peripheral neuropathy","otherDrugs":[{"name":"duloxetine","slug":"duloxetine","company":"Lilly"},{"name":"pregabalin","slug":"pregabalin","company":"Pf Prism Cv"},{"name":"thioctic acid","slug":"thioctic-acid","company":""}],"globalPrevalence":null},{"indication":"Peripheral neuropathic pain","otherDrugs":[{"name":"pregabalin","slug":"pregabalin","company":"Pf Prism Cv"}],"globalPrevalence":null},{"indication":"Postherpetic neuralgia","otherDrugs":[{"name":"capsaicin","slug":"capsaicin","company":"Acorda"},{"name":"gabapentin","slug":"gabapentin","company":"Pfizer Pharms"},{"name":"gabapentin enacarbil","slug":"gabapentin-enacarbil","company":"Xenoport Inc"},{"name":"lidocaine","slug":"lidocaine","company":"Fresenius Kabi Usa"}],"globalPrevalence":null}],"mechanism":{"target":"Voltage-dependent calcium channel subunit alpha-2/delta-1","targets":[{"gene":"CACNA2D1","source":"DrugCentral","target":"Voltage-dependent calcium channel subunit alpha-2/delta-1","protein":"Voltage-dependent calcium channel subunit alpha-2/delta-1"},{"gene":"CACNA2D2","source":"DrugCentral","target":"Voltage-dependent calcium channel subunit alpha-2/delta-2","protein":"Voltage-dependent calcium channel subunit alpha-2/delta-2"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Mirogabalin selectively binds to the alpha-2/delta-1 subunit of voltage-dependent calcium channels, which are involved in the regulation of neurotransmitter release and neuronal excitability. By blocking these channels, Mirogabalin reduces the influx of calcium ions into neurons, leading to a decrease in pain transmission."},"commercial":{"revenueYear":2024,"annualRevenue":300,"revenueSource":"Verified: Daiichi Sankyo AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5491","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MIROGABALIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIROGABALIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:48:27.170613","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:33:21.563474+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gabapentin","drugSlug":"gabapentin","fdaApproval":"1993-12-30","genericCount":47,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pregabalin","drugSlug":"pregabalin","fdaApproval":"2004-12-30","patentExpiry":"Nov 2, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"mirogabalin","indications":{"approved":[{"name":"Diabetic peripheral neuropathy","source":"DrugCentral","snomedId":424736006,"regulator":"FDA"},{"name":"Peripheral neuropathic pain","source":"DrugCentral","snomedId":279981003,"regulator":"FDA"},{"name":"Postherpetic neuralgia","source":"DrugCentral","snomedId":2177002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"gabapentin","brandName":"gabapentin","genericName":"gabapentin","approvalYear":"1993","relationship":"same-class"},{"drugId":"pregabalin","brandName":"pregabalin","genericName":"pregabalin","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07307170","phase":"NA","title":"The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":["Herpes Zoster","Mirogabalin","Pain"],"enrollment":750,"completionDate":"2027-12-31"},{"nctId":"NCT07451431","phase":"PHASE4","title":"Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain","status":"RECRUITING","sponsor":"Bangladesh Medical University","startDate":"2025-10-01","conditions":["Diabetic Peripheral Neuropathic Pain (DPNP)"],"enrollment":78,"completionDate":"2027-05"},{"nctId":"NCT07157852","phase":"NA","title":"The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-09-05","conditions":["Fibromyalgia","Pregabalin","Mirogabalin","Pain"],"enrollment":674,"completionDate":"2027-08-31"},{"nctId":"NCT06328062","phase":"NA","title":"Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA","status":"RECRUITING","sponsor":"Thammasat University Hospital","startDate":"2024-04-01","conditions":["Pain Postoperative","Osteoarthritis","Total Knee Arthroplasty"],"enrollment":80,"completionDate":"2025-05-31"},{"nctId":"NCT06846567","phase":"PHASE1","title":"Phase I Study of BM2216 ER vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults","status":"COMPLETED","sponsor":"Zhejiang Anglikang Pharmaceutical Co., Ltd.","startDate":"2024-12-01","conditions":["Diabetic Neuropathies","Diabetes Mellitus"],"enrollment":66,"completionDate":"2025-01-12"},{"nctId":"NCT06812117","phase":"","title":"A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-01-25","conditions":["Diabetic Peripheral Neuropathic Pain"],"enrollment":720,"completionDate":"2026-04-13"},{"nctId":"NCT06711978","phase":"NA","title":"Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors","status":"NOT_YET_RECRUITING","sponsor":"Pusan National University Yangsan Hospital","startDate":"2024-12-01","conditions":["CIPN","CIPN - Chemotherapy-Induced Peripheral Neuropathy","CIPN in Adjuvant Breast Cancer Patients","Duloxetine","Mirogabalin"],"enrollment":66,"completionDate":"2025-06-30"},{"nctId":"NCT03901352","phase":"PHASE3","title":"Study of Mirogabalin for Central Neuropathic Pain","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2019-03-12","conditions":["Central Neuropathic Pain"],"enrollment":300,"completionDate":"2020-12-28"},{"nctId":"NCT05938088","phase":"NA","title":"Mirogabalin for Total Hip Arthroplasty","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2023-07-20","conditions":["Hip Osteoarthritis"],"enrollment":56,"completionDate":"2025-06-28"},{"nctId":"NCT04094662","phase":"PHASE3","title":"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2019-09-18","conditions":["Diabetic Peripheral Neuropathic Pain"],"enrollment":393,"completionDate":"2022-01-24"},{"nctId":"NCT02607280","phase":"PHASE3","title":"DS-5565 Phase III Study for Renal Impairment in Japanese Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-12","conditions":["Diabetic Peripheral Neuropathic Pain","Post-herpetic Neuralgia"],"enrollment":35,"completionDate":"2017-03"},{"nctId":"NCT01496365","phase":"PHASE2","title":"Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2011-11-28","conditions":["Diabetic Peripheral Neuropathy"],"enrollment":452,"completionDate":"2012-09-07"},{"nctId":"NCT02496884","phase":"PHASE3","title":"Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-06-26","conditions":["Fibromyalgia"],"enrollment":56,"completionDate":"2017-07-06"},{"nctId":"NCT02187471","phase":"PHASE3","title":"Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-01-16","conditions":["Pain Associated With Fibromyalgia"],"enrollment":1301,"completionDate":"2017-01-12"},{"nctId":"NCT02187159","phase":"PHASE3","title":"Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-11","conditions":["Pain Associated With Fibromyalgia"],"enrollment":1270,"completionDate":"2016-07-07"},{"nctId":"NCT02146430","phase":"PHASE3","title":"Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-10-27","conditions":["Pain Associated With Fibromyalgia"],"enrollment":1293,"completionDate":"2016-07-14"},{"nctId":"NCT02318719","phase":"NA","title":"DS-5565 Phase III Study for Post-herpetic Neuralgia","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-01","conditions":["Post-Herpetic Neuralgia"],"enrollment":765,"completionDate":"2017-05-25"},{"nctId":"NCT02318706","phase":"PHASE3","title":"DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-01","conditions":["Diabetic Peripheral Neuropathic Pain"],"enrollment":854,"completionDate":"2017-06-29"},{"nctId":"NCT02234583","phase":"PHASE3","title":"An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-02-04","conditions":["Pain Associated With Fibromyalgia"],"enrollment":2485,"completionDate":"2017-04-19"},{"nctId":"NCT01504412","phase":"PHASE2","title":"Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2012-01","conditions":["Pain","Diabetic Peripheral Neuropathy"],"enrollment":450,"completionDate":"2013-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"S7LK2KDM5U","INN_ID":"9767","UMLSCUI":"C4043827","chemblId":"CHEMBL3545125","ChEMBL_ID":"CHEMBL3545257","KEGG_DRUG":"D10790","DRUGBANK_ID":"DB11825","PDB_CHEM_ID":" 8X9","PUBCHEM_CID":"59509752","IUPHAR_LIGAND_ID":"8303","MESH_SUPPLEMENTAL_RECORD_UI":"C000598618"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Daiichi Sankyo Company, Limited","relationship":"Current Owner"}],"publicationCount":169,"therapeuticAreas":["Metabolic"],"_revenueScrapedAt":"2026-04-08 13:59:18.842964+00","atcClassification":{"source":"DrugCentral","atcCode":"N02BF03","allCodes":["N02BF03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Daiichi Sankyo","companyId":"daiichi-sankyo","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2019-08-01T00:00:00.000Z","mah":"DAIICHI SANKYO COMPANY, LIMITED","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:33:21.563474+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}